Year-end report July 1, 2021 – June 30, 2022
30 August, 2023
By “Company” or “DexTech” is meant DexTech Medical AB with organization number 556664-6203.
Summary of the fourth quarter (2022-04-01 – 2022-06-30)
- Net sales amounted to MSEK 0,0 (0,0)
- Operating profit/loss amounted to MSEK -1,3 (-2,1)
- Earnings per share* SEK -0.06 (-0.11)
* Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average number of shares was 18,485,857. Amounts in brackets refer to the corresponding period last year.
Summary of the financial year (2021-07-01 – 2022-06-30)
- Net sales amounted to MSEK 0,0 (0,0)
- Operating profit/loss amounted to MSEK -4,9 (-5,3)
- Earnings per share* SEK -0.25 (-0.31)
- Cash and cash equivalents at the end of the period amounted to MSEK 25,2 (35,5)
* Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average number of shares was 16,790,364. Amounts in brackets refer to the corresponding period last year.
CEO’s comment
The company’s phase 1 study regarding OsteoDex’s treatment of multiple myeloma is underway and patient recruitment is ongoing.
The principal investigator (PI) is Dr. Katarina Uttervall, MD, PhD, Department of Hematology/HERM, Karolinska University Hospital, Huddinge. Biomarkers are analysed at the Central Laboratory, Karolinska University Hospital, NKS, Solna. Patients with relapsed/treatment-resistant disease and who have received 1–3 previous lines of treatment are included. The primary objective is to confirm safety and tolerability and, as a secondary objective, to determine any treatment response. Documentation of quality of life will also be done (QoL scores).
Study material, GMP manufactured OsteoDex, is produced by Biovian OY, Turku, Finland and is delivered to the respective hospitals. We look forward to conducting this study.
Anders R Holmberg
CEO